Beximco Pharmaceuticals Limited has resumed trading on the London Stock Exchange after a suspension of nearly six months over its failure to publish annual financial results on time.
The exchange lifted the freeze on Friday, with trading in the company's Global Depositary Receipts (GDRs) resuming on the Alternative Investment Market (AIM) on Friday and Saturday.
The exchange informed investors that Beximco Pharma had published its financial reports, which were now available on the platform.
The company’s GDRs were suspended from 7:30am London time on Jan 2 after it said in December that it would miss the Dec 31 deadline to publish its annual report and audited accounts for the financial year ending Jun 30, 2025, under AIM Rule 19.
The suspension put Beximco Pharma at risk of being delisted altogether.
Six institutional investors holding the company's London-listed securities wrote to the Bangladesh Securities and Exchange Commission (BSEC) in Dhaka, urging it to help find an honourable resolution.
The BSEC responded by granting special permission for Beximco Pharma to hold a board meeting.
The board convened on Jun 23 and approved both the audited annual and unaudited quarterly financial reports for publication.
At the same meeting, the board approved a 47.5 percent cash dividend for the year ending June last year, pending ratification at the annual general meeting (AGM).
The AGM date is yet to be announced, pending court approval, with Aug 2 set as the record date.
The company's earnings per share for 2025 came in at Tk 15.56, up from Tk 13.07 the previous year.